MarginsXMarginsX
Home › Markets › Health Care › PRTA

Prothena Corporation plc (PRTA)

PRTA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$7.97
-2.33% on the day
Market cap
$409.3M
Small cap
Revenue · 2025
$9.7M
-92.8% on 2024
Net income · 2025
-$244.1M
-2520.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1559053/000155905326000008/0001559053-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerPRTA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001559053
SEC industry codePharmaceutical Preparations
Incorporated inIreland

Financials · 2025

LineValue
Revenue$9.7M
Net income-$244.1M
Operating income-$214.6M
Net margin-2520.6%
Operating margin-2216.4%
Revenue growth-92.8%
Cash$307.5M
Total assets$326.8M
P/E (computed)Net income was not positive
P/S (computed)42.3×

Warning signs

Cash runway
103.6 months
$271.4M cash at September 30, 2026
Share count, 1 year
-4.6%
2025-10-31 to 2026-10-29 · -4.3% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$7.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$271.4M cash; operating cash flow -$7.9M a quarter.Report 2026-09-30
Shares outstanding51,349,796 (2026-10-29); 53,829,982 a year earlier; 53,665,349 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $7.3M, sold $136K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$620K-$16.5M-$12.0M$271.4MNo debt tags$52.7M10-Q 2026-11-05
Q2 2026
2026-06-30
$1.0M-$18.6M-$25.0M$288.2MNo debt tags$54.5M10-Q 2026-08-06
Q1 2026
2026-03-31
$51.1M$32.7M$28.9M$329.5MNo debt tags$57.9M10-Q 2026-05-07
Q4 2025
2025-12-31
$21K-$21.6M-$23.3M$307.5MNo debt tags$9.7M10-K 2026-02-27
Q3 2025
2025-09-30
$2.4M-$36.5M-$40.6M$330.8MNo debt tags$11.8M10-Q 2026-11-05
Q2 2025
2025-06-30
$4.4M-$125.8M-$46.3M$371.4MNo debt tags$10.3M10-Q 2026-08-06
Q1 2025
2025-03-31
$2.8M-$60.2M-$53.4M$417.9MNo debt tags$137.9M10-Q 2026-05-07
Q4 2024
2024-12-31
$2.1M-$58.0M-$47.8M$471.4MNo debt tags$135.2M10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-02-27
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-03-27

Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+2.4%
1 month-2.4%
3 months-10.1%
Year to date-14.6%
1 year-19.8%
From 52-week high-29.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PEPGPepGen Inc.$4.19-3.90%$395.0M
AVTXAvalo Therapeutics Inc.$7.37-5.03%$426.2M
IRDOpus Genetics Inc.$4.04+1.51%$390.5M
CTMXCytomX Therapeutics Inc.$1.99-2.70%$432.7M
BLSMBlossomHill Therapeutics Inc.$13.65-2.64%$433.9M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M
ASMBAssembly Biosciences Inc.$21.29+0.80%$436.0M
CRMDCorMedix Inc.$4.82+3.43%$383.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier